ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making


Autoria(s): Schmoll, H. J.; Van Cutsem, E.; Stein, A.; Valentini, V.; Glimelius, B.; Haustermans, K.; Nordlinger, B.; van de Velde, C. J.; Balmana, J.; Regula, J.; Nagtegaal, I. D.; Beets-Tan, R. G.; Arnold, D.; Ciardiello, F.; Hoff, P.; Kerr, D.; Koehne, C. H.; Labianca, R.; Price, T.; Scheithauer, W.; Sobrero, A.; Tabernero, J.; Aderka, D.; Barroso, S.; Bodoky, G.; Douillard, J. Y.; El Ghazaly, H.; Gallardo, J.; Garin, A.; Glynne-Jones, R.; Jordan, K.; Meshcheryakov, A.; Papamichail, D.; Pfeiffer, P.; Souglakos, I.; Turhal, S.; Cervantes, A.
Contribuinte(s)

UNIVERSIDADE DE SÃO PAULO

Data(s)

15/10/2013

15/10/2013

2012

Resumo

Colorectal cancer (CRC) is the most common tumour type in both sexes combined in Western countries. Although screening programmes including the implementation of faecal occult blood test and colonoscopy might be able to reduce mortality by removing precursor lesions and by making diagnosis at an earlier stage, the burden of disease and mortality is still high. Improvement of diagnostic and treatment options increased staging accuracy, functional outcome for early stages as well as survival. Although high quality surgery is still the mainstay of curative treatment, the management of CRC must be a multi-modal approach performed by an experienced multi-disciplinary expert team. Optimal choice of the individual treatment modality according to disease localization and extent, tumour biology and patient factors is able to maintain quality of life, enables long-term survival and even cure in selected patients by a combination of chemotherapy and surgery. Treatment decisions must be based on the available evidence, which has been the basis for this consensus conference-based guideline delivering a clear proposal for diagnostic and treatment measures in each stage of rectal and colon cancer and the individual clinical situations. This ESMO guideline is recommended to be used as the basis for treatment and management decisions.

Roche

Merck Serono

Sanofi Aventis

AstraZeneca

Genomic Health

BMS

Amgen

Bayer

Novartis

Identificador

ANNALS OF ONCOLOGY, OXFORD, v. 23, n. 10, pp. 2479-2516, OCT, 2012

0923-7534

http://www.producao.usp.br/handle/BDPI/35136

10.1093/annonc/mds236

http://dx.doi.org/10.1093/annonc/mds236

Idioma(s)

eng

Publicador

OXFORD UNIV PRESS

OXFORD

Relação

ANNALS OF ONCOLOGY

Direitos

restrictedAccess

Copyright OXFORD UNIV PRESS

Palavras-Chave #METASTATIC COLORECTAL-CANCER #RANDOMIZED PHASE-III #CAPECITABINE PLUS OXALIPLATIN #LONG-TERM SURVIVAL #ANGIOGENESIS INHIBITOR BEVACIZUMAB #GROWTH-FACTOR RECEPTOR #LIVER-ONLY METASTASES #GENE MUTATION STATUS #MRC COIN TRIAL #1ST-LINE TREATMENT #ONCOLOGY
Tipo

article

original article

publishedVersion